Last week I stood up at M&M and presented two dead deals. Both clinical aesthetics. Both in the same market. Both killed by the same lesson: the financial structure filter has to run earlier.

This week the board is clear. No broker calls. No outreach. No new deals on the radar worth advancing. The sourcing tools are running. The filters are holding. And in the middle of a quiet week, a banker's email taught me more about deal evaluation than any listing I've screened in twenty-three weeks.

———

In the ER, when EMS wheels in a patient, they hand you a set of vitals. Blood pressure. Heart rate. Oxygen saturation. Numbers taken in a moving ambulance, on different equipment, minutes ago.

The first thing we do is retake every one. Not because the medics got it wrong — because those vitals were measured in a different context, on a different monitor. Until my equipment confirms them, they're the story of the patient. Not the patient.

I'd asked our SBA lending team a simple question: when a broker says "we have lenders willing to lend up to X," what does that actually mean? The answer was clarifying. It means almost nothing. Those numbers haven't been through underwriting — and underwriting doesn't happen until a specific buyer has an accepted LOI and credit is pulled. The lender won't even confirm which add-backs they'll accept until they see the full picture: buyer and business together.

Field vitals.

Here's the principle I'm taking from it. Every number in a deal has a source, and the source determines how much weight it carries. Seller-reported numbers — the CIM, the broker's pitch, "lenders will finance this" — are vitals taken in the back of the ambulance. Verified numbers — tax returns, bank statements — are your own monitor. Underwritten numbers are the labs.

You don't ignore the first set. You just never treat off of them.

That's the M&M lesson from last week, sharpened. I spent weeks building conviction on operations and market fit using seller-reported data before I stress-tested it against my own financial structure. The deals died at the monitor, not in the field. Next time, I run my own vitals before I fall in love with someone else's.

The sourcing tools ran all week. Listings hit the radar. Every one carried seller-reported numbers — revenue claims, margin projections, asking prices. The filters screened them against the deal box. None survived first contact. And that's the system doing its job: not finding deals, but eliminating the ones that don't clear the first set of vitals before I ever take my own.

———

Pipeline is clear. Sourcing tools running. Filters holding. No outreach sent this week — and that's fine. The system is doing what it's supposed to do: screening automatically and waiting for something that clears the bar.

The deal team is staying warm without burning it. The attorney I was introduced to during the med spa process offered a consultation — I declined until there's a live transaction. No point spending consult time on a hypothetical. She appreciated the directness and left the door open.

A reader replied to last week's M&M with a stat that stuck with me: average conversion in this space runs about ten percent. Ten offers to get one accepted. We've made one. If the average holds, we're a tenth of the way through the reps. That number could be discouraging or clarifying, depending on how you read it. I'm choosing clarifying.

———

Keep sourcing. Keep the filters running. Keep the discipline that M&M installed: financial structure first, before the site visit, before the attorney, before I build the team around a deal.

And keep the second-set-of-vitals principle operating at every stage. The CIM is the field report. The tax returns are my monitor. Underwriting is the lab. Every number gets sourced before it gets trusted.

Twenty-three weeks. The board is clear. The deal team is warm. And the next listing that clears the bar will get a better workup than the last two — because the physician running it has been through M&M and knows which vitals to retake first.

———

— Joe & Lacy

Take your own vitals. Every time.

Subscribe to Acquisition Rx | Follow on X | LinkedIn